Literature DB >> 27651240

Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.

A K Hemanth Kumar1, V Chandrasekaran1, T Kannan1, A Lakshmi Murali2, J Lavanya3, V Sudha1, Soumya Swaminathan1, Geetha Ramachandran4.   

Abstract

PURPOSE: The aim of the study was to compare plasma concentrations of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between tuberculosis (TB) patients with and without diabetes mellitus (DM).
METHODS: Two-hour post-dosing concentrations of RMP, INH and PZA were determined in adult TB patients that were studied with (n = 452) and without DM (n = 1460), treated with a thrice-weekly regimen in India. Drug concentrations were estimated by HPLC.
RESULTS: The median (IQR) INH [6.6 (3.9-10.0) and 7.8 (4.6-11.3)] and PZA [31.0 (22.3-38.0) and 34.1 (24.6-42.7)] microgram per milliliter concentrations were significantly lower in diabetic than non-diabetic TB patients (p < 0.001 for both drugs). Blood glucose was negatively correlated with plasma INH (r = -0.09, p < 0.001) and PZA (r = -0.092, p < 0.001). Multiple linear regression analysis showed RMP, INH and PZA concentrations were influenced by age and drug doses, INH and PZA by DM, RMP by alcohol use and PZA by gender and category of ATT. DM reduced INH and PZA concentrations by 0.8 and 3.0 μg/ml, respectively.
CONCLUSIONS: TB patients with DM had lower INH and PZA concentrations. Negative correlation between blood glucose and drug concentrations suggests delayed absorption/faster elimination of INH and PZA in the presence of elevated glucose.

Entities:  

Keywords:  Anti-tuberculosis drug concentrations; Diabetes mellitus; Revised National Tuberculosis Control Programme; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27651240     DOI: 10.1007/s00228-016-2132-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

Authors:  Hanneke M J Nijland; Rovina Ruslami; Janneke E Stalenhoef; Erni J Nelwan; Bachti Alisjahbana; Ron H H Nelwan; Andre J A M van der Ven; Halim Danusantoso; Rob E Aarnoutse; Reinout van Crevel
Journal:  Clin Infect Dis       Date:  2006-08-22       Impact factor: 9.079

2.  Will China's nutrition transition overwhelm its health care system and slow economic growth?

Authors:  Barry M Popkin
Journal:  Health Aff (Millwood)       Date:  2008 Jul-Aug       Impact factor: 6.301

Review 3.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

5.  Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients.

Authors:  Min Jung Chang; Jung-Woo Chae; Hwi-Yeol Yun; Jangik I Lee; Hye Duck Choi; Jihye Kim; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Wan Gyoon Shin; Jae-Ho Lee
Journal:  Tuberculosis (Edinb)       Date:  2014-11-15       Impact factor: 3.131

6.  Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study.

Authors:  Dariush Mozaffarian; Aruna Kamineni; Mercedes Carnethon; Luc Djoussé; Kenneth J Mukamal; David Siscovick
Journal:  Arch Intern Med       Date:  2009-04-27

7.  Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients.

Authors:  R Singla; N Khan; N Al-Sharif; M O Ai-Sayegh; M A Shaikh; M M Osman
Journal:  Int J Tuberc Lung Dis       Date:  2006-01       Impact factor: 2.373

8.  Type 2 diabetes and multidrug-resistant tuberculosis.

Authors:  Susan P Fisher-Hoch; Erin Whitney; Joseph B McCormick; Gonzalo Crespo; Brian Smith; Mohammad H Rahbar; Blanca I Restrepo
Journal:  Scand J Infect Dis       Date:  2008

9.  Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.

Authors:  A K Hemanth Kumar; T Kannan; V Chandrasekaran; V Sudha; A Vijayakumar; K Ramesh; J Lavanya; S Swaminathan; G Ramachandran
Journal:  Int J Tuberc Lung Dis       Date:  2016-09       Impact factor: 2.373

10.  Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Authors:  Rovina Ruslami; Hanneke M J Nijland; I Gusti N Adhiarta; Sri H K S Kariadi; Bachti Alisjahbana; Rob E Aarnoutse; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

View more
  10 in total

1.  Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

Authors:  Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton
Journal:  Tuberculosis (Edinb)       Date:  2018-10-01       Impact factor: 3.131

Review 2.  Alterations in pancreatic β cell function and Trypanosoma cruzi infection: evidence from human and animal studies.

Authors:  Quinn Dufurrena; Farhad M Amjad; Philipp E Scherer; Louis M Weiss; Jyothi Nagajyothi; Jesse Roth; Herbert B Tanowitz; Regina Kuliawat
Journal:  Parasitol Res       Date:  2016-12-24       Impact factor: 2.289

3.  Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Authors:  Omamah Alfarisi; Vidya Mave; Sanjay Gaikwad; Tushar Sahasrabudhe; Geetha Ramachandran; Hemanth Kumar; Nikhil Gupte; Vandana Kulkarni; Sona Deshmukh; Sachin Atre; Swapnil Raskar; Rahul Lokhande; Madhusudan Barthwal; Arjun Kakrani; Sandy Chon; Amita Gupta; Jonathan E Golub; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

4.  Clincal interpretation of the anti-tuberculosis drug concentrations in diabetic and non-diabetic tuberculosis patients.

Authors:  Nilan T Jacob
Journal:  Eur J Clin Pharmacol       Date:  2017-04-17       Impact factor: 2.953

Review 5.  A narrative review of tuberculosis in the United States among persons aged 65 years and older.

Authors:  Iris L Wu; Amit S Chitnis; Devan Jaganath
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-06-13

6.  A Simple and Sensitive UPLC-UV Method for Simultaneous Determination of Isoniazid, Pyrazinamide, and Rifampicin in Human Plasma and Its Application in Therapeutic Drug Monitoring.

Authors:  Zhimei Jiang; Liang Huang; Lingli Zhang; Qin Yu; Yunzhu Lin; Haotian Fei; Hongxin Shen; Hong Huang
Journal:  Front Mol Biosci       Date:  2022-04-29

7.  Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus.

Authors:  Chikako Ichikawa; Sho Tanaka; Masahiro Takubo; Masaru Kushimoto; Jin Ikeda; Katsuhiko Ogawa; Ichiro Tsujino; Yutaka Suzuki; Masanori Abe; Hisamitsu Ishihara; Midori Fujishiro
Journal:  Ther Clin Risk Manag       Date:  2021-05-25       Impact factor: 2.423

8.  Development and Application of a LC-MS/MS Method for Simultaneous Quantification of Four First-Line Antituberculosis Drugs in Human Serum.

Authors:  Yunliang Zheng; Nana Xu; Xingjiang Hu; Qiao Zhang; Yanpeng Liu; Qingwei Zhao
Journal:  J Anal Methods Chem       Date:  2020-07-08       Impact factor: 2.193

Review 9.  The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice.

Authors:  Reinout van Crevel; Julia A Critchley
Journal:  Trop Med Infect Dis       Date:  2021-01-08

Review 10.  Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia.

Authors:  Minh Dao Ngo; Stacey Bartlett; Katharina Ronacher
Journal:  Microorganisms       Date:  2021-11-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.